Australian Kalydeco decision 'deferred,' patients will fight but need a champion

Cystic fibrosis patients in Australia have lost round one in their battle to get affordable access to Vertex's Kalydeco, after the government-appointed body in charge of granting treatments for reimbursement deferred making a decision on the drug because it is priced too high. Patients in Australia who are eligible for the drug, which is used to treat CF sufferers with the G551D gene, say they feel they have no one "championing" their fight.